Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of active pharmaceutical ingredients. It offers gliclazide, for the treatment of NIDDM; metformin hydrochloride used as an adjunct to diet and exercise in adult patients with NIDDM; isosorbide mononitrate for prevention of angina pectoris and treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction; isosorbide dinitrate to prevent angina pectoris due to coronary artery disease; mecobalamin for peripheral neuropathies; lansoprazole to treat acid-reflux disorders, peptic ulcer disease, h. pylori eradication, and prevention of gastrointestinal bleeds; ropivacaine hydrochloride for obstetric and regional anesthesia; isoflurane; fluoxetine hydrochloride, an anti-depression drug; clemastine fumarate, an anti-allergic agent; isoprenaline hydrochloride to treat mild or transient episodes of heart block; esmolol hydrochloride for the rapid control of ventricular rate; xanthinol nicotinate to treat of brain function barrier, cerebral embolism and cerebral thrombosis; amlexanox for treatment of aphthous ulcers; nisolsipine for hypertension; clarithromycin lactobionate; trepibutone; propafenone hydrochloride; diclofenac potassium to treat osteoarthritis and rheumatoid arthritis; chlorzoxazone for relief of discomfort associated with acute painful musculoskeletal conditions; esomeprazole sodium treats related gastric ulcer disease and zollinger-ehrlich syndrome; palonosetron hydrochloride, a chemotherapy adjuvant medication; edaravone, a cerebral protective agent; vildagliptin to treat diabetes; etamsylate, a hemostatic medication; pranoprofen that is a non-steroidal anti-inflammatory analgesic and antipyretic drugs; parecoxib sodium; and lurasidone hydrochloride, a medication for schizophrenia. The company was incorporated in 2004 and is headquartered in Jinan, China.
Metrics to compare | 301281 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship301281PeersSector | |
---|---|---|---|---|
P/E Ratio | 58.8x | 30.5x | −0.5x | |
PEG Ratio | −8.99 | −0.65 | 0.00 | |
Price/Book | 2.6x | 1.8x | 2.6x | |
Price / LTM Sales | 8.5x | 3.0x | 3.0x | |
Upside (Analyst Target) | - | 13.8% | 48.7% | |
Fair Value Upside | Unlock | 13.9% | 9.2% | Unlock |